FM19G11 is primarily researched for its potential applications in the field of cancer therapy, particularly in targeting hypoxic conditions within tumors. It has shown promise in inhibiting hypoxia-inducible factors (HIFs), which play a critical role in tumor survival and progression under low oxygen conditions. By disrupting HIF activity, FM19G11 may help reduce tumor growth, angiogenesis, and metastasis. This makes it a candidate for combination therapies with other anticancer agents to enhance treatment efficacy. Additionally, its mechanism of action is being explored for potential use in other diseases where hypoxia is a contributing factor, such as certain inflammatory and cardiovascular conditions. Research is ongoing to further understand its therapeutic potential and optimize its application in clinical settings.